جستجوی استاد راهنمای دانشگاهی

Dr. Camila Aquino serves as Assistant Professor in both the Department of Clinical Neurosciences and Department of Community Health Sciences at the University of Calgary's Cumming School of Medicine, and is a Full Member of the Hotchkiss Brain Institute. As Medical Director of the Deep Brain Stimulation Program, she specializes in Parkinson's disease, essential tremor, dystonia, and chorea management, including EMG-guided botulinum toxin injections. Her educational background includes: M.D. in Medicine from Escola Superior de Ciencias da Santa Casa (2005) M.S. in Neurosciences from Federal University of Sao Paulo (2012) Ph.D. in Neurosciences from Federal University of Sao Paulo (2019) M.S. in Health Research Methods, Clinical Epidemiology from McMaster University (2020) Dr. Aquino's research addresses unmet needs in movement disorders through innovative clinical trial designs for Parkinson's disease, focusing on precision-medicine approaches, early intervention, and outcome optimization. She actively evaluates neuromodulation therapies including Deep Brain Stimulation, Spinal Cord Stimulation, and MRgFUS, with emphasis on expanding indications and improving patient outcomes. As an International Parkinson and Movement Disorder Society member, she chairs the web-based learning committee and serves on evidence-based medicine and outcome measure committees. Analysis of her 15 most recent publications (2021-2025) reveals a cohesive research trajectory centered on Parkinson's disease management, with dominant themes in motor fluctuation treatments, deep brain stimulation methodology, and clinical trial innovation. Her work bridges fundamental clinical practice guidelines with advanced neuromodulation technologies, demonstrating consistent commitment to evidence-based solutions for movement disorders. Her scientific recognition includes: Parkinson Canada research grant Mohammed Al Zaibak Foundation scholarship CAPES scholarship from Brazilian Ministry of Education Dr. Aquino has secured significant research funding supporting clinical trials in Parkinson's disease neuroprotection and neuromodulation therapies. While specific student advisees aren't listed, her leadership of the DBS Program and active clinical trial portfolio indicate substantial mentorship responsibilities. Her grant portfolio emphasizes translational research with direct clinical impact. She directs the University of Calgary's Deep Brain Stimulation Program and contributes to the MRI-guided focused ultrasound initiative. Through her International Parkinson and Movement Disorder Society committee roles, she shapes global educational standards and evidence-based practices in movement disorders.

• Movement Disorders
• Parkinson's Disease
• Deep Brain Stimulation
• +۵ مورد دیگر

Professor Maria Craig is a distinguished academic and researcher at the University of New South Wales, Faculty of Medicine & Health, specializing in childhood diabetes research. She holds a prominent position as a Professor with extensive contributions to the field of pediatric endocrinology and diabetes, particularly focusing on type 1 diabetes in children. Professor Craig's educational background includes: MB BS from the University of Melbourne MMedSc(ClinEpid) from the University of Newcastle PhD from the University of Sydney FRACP (Fellow of the Royal Australasian College of Physicians) Professor Craig's research primarily focuses on childhood diabetes, with special emphasis on prediction and prevention of type 1 diabetes. She has a significant interest in the association between viruses and type 1 diabetes, collaborating with the Virology Research Group at Prince of Wales Hospital (POWH). Together with Professor Bill Rawlinson, she leads the viral theme for the multicentre ENDIA study (endia.org.au). As principal investigator for the CoRD trial, she is conducting a world-first phase 1 study using autologous cord blood for prevention of type 1 diabetes in children with islet autoimmunity. Additionally, she serves as principal investigator for the Australasian Diabetes Data Network (ADDN). Her research portfolio also encompasses the epidemiology of various forms of childhood diabetes (type 1, type 2, cystic fibrosis related diabetes and monogenic diabetes) and diabetes complications, in collaboration with Professor Kim Donaghue at the Children's Hospital at Westmead. Professor Craig's extensive publication record, including over 361 journal articles, demonstrates her leadership in advancing our understanding of childhood diabetes. Her recent work shows increasing focus on early detection methods, risk prediction models, technological interventions for diabetes management, and the complex interplay between viral infections and autoimmune diabetes development. She has been instrumental in developing clinical practice guidelines through her role as co-editor of the International Society for Pediatric and Adolescent Diabetes (ISPAD) guidelines. Professor Craig has received numerous prestigious awards recognizing her contributions to pediatric endocrinology and diabetes research: Australian Paediatric Endocrine Group Young Investigator's Award (1997) Asia Pacific Paediatric Endocrine Society Clinical Teaching Award (2008) Lifetime Honorary Member, Caring and Living as Neighbours (2013) Australian Diabetes Society Jeff Flack Diabetes Data Award (2019) Australian Paediatric Endocrine Group Norman Wettenhall Award for Research and Innovation (2019) Throughout her career, Professor Craig has demonstrated exceptional leadership in professional societies, having served as former president/treasurer of the Australasian Paediatric Endocrine Group (APEG) and currently as Scientific Convenor of the Asia Pacific Paediatric Endocrine Society Fellows school. Her work with the ENDIA study and Australasian Diabetes Data Network represents significant collaborative research efforts involving multiple institutions across Australia and internationally. Her principal investigator roles for major studies indicate substantial research funding support. Professor Craig leads several important research initiatives including the ENDIA study, the CoRD trial, and the Australasian Diabetes Data Network. These programs involve multidisciplinary teams of researchers, clinicians, and support staff working collaboratively to advance understanding and treatment of childhood diabetes. Her work at the intersection of virology and diabetes represents a unique and innovative approach to understanding the environmental triggers of type 1 diabetes.

• Childhood Diabetes
• Type 1 Diabetes
• Virology and Diabetes
• +۴ مورد دیگر

Dr. Keith Alexander Sharkey is a Professor in the Department of Physiology and Pharmacology at the Cumming School of Medicine, University of Calgary. He is also a Full Member of both the Hotchkiss Brain Institute and The Calvin, Phoebe and Joan Snyder Institute for Chronic Diseases. Dr. Sharkey has been at the University of Calgary since his appointment as Assistant Professor in 1990, dedicating his career to understanding the neural control of the gastrointestinal tract. From 2005-2021, he held the Crohn's and Colitis Canada Chair in Inflammatory Bowel Disease Research, demonstrating his longstanding commitment to advancing knowledge in gastrointestinal sciences. Dr. Sharkey's educational journey began with a BSc (Hons) in Nutrition from the University of London in 1981, followed by a PhD in Physiology from the University of Liverpool in 1985. After completing postdoctoral training in Hungary, the UK, and Canada, he joined the University of Calgary faculty in 1990, where he has remained throughout his distinguished academic career. Dr. Sharkey's research program centers on understanding the physiology and pathophysiology of the neural control of the gastrointestinal tract and brain-gut interactions in health and disease. His laboratory investigates two main areas: the role of the endocannabinoid system in regulating GI motility and intestinal barrier function, and the physiology of the enteric nervous system in controlling motility and barrier function. His work employs state-of-the-art approaches including live cell imaging and molecular genetics. Recent publications show his expanding interest in connections between gut function and neurodegenerative conditions like ALS, with multiple 2024-2025 papers examining sexual dimorphism in disease processes and gut-brain axis mechanisms. Fellow, Royal Society of Canada (2024) Cumming School of Medicine's van de Sande Distinguished Achievement Award for Mentorship (2021) Distinguished Research Award, American Physiological Society (2021) Finkelstein Award for Excellence, Crohn's and Colitis Canada (2016) Fellow, Canadian Academy of Health Sciences (2015) Fellow, Canadian Association of Gastroenterology (2015) Killam Annual Professor Award, University of Calgary (2013) Dr. Sharkey has mentored numerous students throughout his career, as evidenced by his 2021 Mentorship Award. His research is supported by significant funding, including a CIHR Foundation grant exploring how enteric nerves and glia maintain intestinal homeostasis. He has also participated in university strategic initiatives focused on Brain and Mental Health (2015-2021) and Infections, Inflammations and Chronic Diseases (2015-2021), demonstrating his interdisciplinary approach. The Sharkey Lab provides a safe, inclusive, and diverse research environment that encourages open scientific exchange from diverse viewpoints. His laboratory is actively engaged in multiple collaborative projects, including investigations with UBC Okanagan on diet and probiotics targeting the gut-brain metabolic interactome, and with University of Calgary colleagues studying gut microbiota's role in ALS. Dr. Sharkey continues to advance our understanding of neural mechanisms controlling gastrointestinal function with upcoming courses scheduled for Fall 2024 and Winter 2025.

• Enteric nervous system
• Gut-brain axis
• Endocannabinoid system
• +۳ مورد دیگر

Daniel Finley is a Professor of Cell Biology at Harvard Medical School (HMS), leading the Finley Lab focused on the ubiquitin-proteasome pathway and related regulatory mechanisms. He holds academic appointments within the Department of Cell Biology and sits on the Scientific Advisory Boards of Proteostasis and X-Chem Pharmaceuticals. His research investigates proteasome function, ubiquitin-like proteins, and proteostasis roles in diseases like Alzheimer’s and ALS. Dr. Finley earned his undergraduate degree in biochemistry from Harvard University and a Ph.D. in molecular biology from MIT. After postdoctoral training at MIT, he joined HMS in 1988. His lab explores topics including erythroid proteome remodeling, mitochondrial dysfunction, and neurodegenerative disease mechanisms. Key research areas include: (1) Ubiquitin-proteasome pathway regulation, (2) Proteasome structure/function, (3) Nonproteolytic roles of ubiquitination, and (4) Pathophysiological roles of proteostasis defects in diseases. His work bridges basic cell biology with translational medicine, particularly in neurodegeneration and anemia. Finley has secured NIH funding for projects like 'Regulation of Proteasome Activity' (R35GM145246) and 'Erythrocyte maturation through global proteome remodeling' (R01HL153970). Collaborations with industry and academic partners extend his impact in drug discovery and proteasome-targeted therapies. His lab’s contributions include defining ubiquitin chain editing mechanisms, identifying USP14’s role in mitophagy, and elucidating proteostasis defects in Alzheimer's models. Research tools developed include advanced cryo-EM analyses of proteasomal structures and functional assays for ubiquitin system enzymes.

• Ubiquitin-Proteasome Pathway
• Proteostasis
• Protein Degradation
• +۷ مورد دیگر

Associate Professor Adam Irwin is an NHMRC Emerging Leadership Fellow and Associate Professor in Infectious Diseases at the University of Queensland (UQ) and Queensland Children’s Hospital. He holds positions within the UQ Centre for Clinical Research, Faculty of Health, Medicine and Behavioural Sciences. His work focuses on early sepsis recognition, antimicrobial stewardship, and pediatric infectious diseases. Dr. Irwin completed his medical degree at the University of Birmingham and his PhD in 2016 from the University of Liverpool’s Institute of Infection and Global Health. He has led initiatives like the Queensland Paediatric Sepsis Program, recognized with a Global Sepsis Alliance Award and Queensland Health Excellence Awards. His research spans sepsis pathway implementation, antimicrobial resistance trends, and rapid diagnostic tools. Notable grants include NHMRC funding for studies on multi-drug resistant infections and Children’s Hospital Foundation support for genomics and antimicrobial stewardship projects. He supervises PhD candidates in areas like bloodstream infections and molecular diagnostics. Dr. Irwin collaborates across institutions, contributing to projects such as the RAPIDS Study Group and the PAEDS surveillance network. Awards include the NHMRC Emerging Leadership Fellowship and recognition for sepsis program excellence. His work emphasizes translating research into clinical practice, improving outcomes for critically ill children through evidence-based protocols and innovative diagnostics.

• Infectious Diseases
• Pediatric Medicine
• Antimicrobial Resistance
• +۳ مورد دیگر

Dr. Pascal Syren is a **Researcher** and **Resident** at Heidelberg University Hospital (UKHD), affiliated with the **Department of Cardiology, Angiology, and Pulmonology** and the **Heidelberg Center for Cardiac Arrhythmias**. His academic role includes contributing to the **Group of Molecular and Translational Cardiac Electrophysiology**, focusing on epigenetic and molecular mechanisms underlying cardiac arrhythmias and heart failure. He holds a PhD from Heidelberg University (2021) on histone deacetylases' influence in cardiac electrophysiology. **Research Interests**: Cardiac electrophysiology, epigenetic regulation (HDACs), ventricular and atrial arrhythmias, echocardiography, and translational cardiology. His work spans basic science to clinical applications, emphasizing ion channel remodeling and therapeutic targets for heart rhythm disorders. **Awards**: Recipient of the **Ernst & Berta Grimmke Foundation Research Grant (2023–2024)** and **Otto-Hess Scholarship (2017–2018)** from the German Cardiac Society. His research bridges molecular mechanisms with clinical cardiology, with contributions to understanding HDAC2's role in action potential dynamics. **Publications**: Over 8 peer-reviewed articles (2016–2025) in journals like *Basic Research in Cardiology* and *Cells*, focusing on histone deacetylase pathways, atrial fibrillation, and ventricular arrhythmia models. Recent work explores neonatal cardiomyocyte electrophysiology and TREK-1 potassium channels in heart failure. **Affiliations**: Active member of the **German Cardiac Society (DGK)** and **European Society of Cardiology (ESC)**, contributing to interdisciplinary cardiac arrhythmia research at Heidelberg's medical faculty.

• Cardiac Electrophysiology
• Histone Deacetylases
• Ventricular Arrhythmias
• +۳ مورد دیگر

Michael Yeager, PhD, serves as an Associate Clinical Professor in the School of Medicine at the University of Colorado Denver, focusing on cardiopulmonary pathophysiology with emphasis on pulmonary hypertension and heart failure mechanisms. He completed his PhD at the University of Colorado Health Sciences Center in 2002, establishing foundational expertise in vascular biology. His research program investigates immunological and molecular drivers of pulmonary vascular disease, particularly the roles of autoantibodies, fibrocytes, and inflammatory cascades in disease progression. Analysis of his 14 publications (2012-2015) reveals consistent exploration of biomarker discovery, vascular remodeling, and immune dysregulation across pediatric and adult pulmonary hypertension. Key methodological approaches include proteomics, animal modeling, and molecular interrogation of cellular stress responses, with significant translational implications for personalized therapeutic strategies. Professional recognitions include: Outstanding Faculty award from Tau Beta Pi (2019) Chancellor's Teaching Recognition Award from the University of Colorado (2016) Dr. Yeager maintains active clinical research collaborations at Children's Hospital Colorado while mentoring within the medical school curriculum. His work bridges basic science discovery with clinical application through ongoing investigations into endothelial dysfunction and inflammatory mediators. Affiliated with the Department of Medicine, he contributes to pulmonary vascular research initiatives and participates in professional societies including the American Thoracic Society, American Heart Association, and T21 Research Society.

• Pulmonary vasculature
• Heart Failure
• Cardiopulmonary Immunology

Dr. Birgit Frauscher is the Lincoln Financial Group Distinguished Professor in Neurobiology at Duke University School of Medicine, where she serves as Professor of Neurology and holds a secondary appointment in the Department of Biomedical Engineering at the Duke Pratt School of Engineering. She is currently the Director of the Duke Comprehensive Epilepsy Center and leads the Analytical Neurophysiology (ANPHY) Lab. Her clinical and research work focuses on epilepsy and sleep medicine, utilizing both invasive and non-invasive electrical recordings to study brain activity in humans. Dr. Frauscher completed her medical training, neurology residency, and subspecialty training in electroencephalography, epilepsy, and sleep medicine at the Medical University of Innsbruck in Austria. After completing her clinical training in 2008, she earned her habilitation degree in 2011. She further specialized in intracranial EEG and signal analysis during a visiting professorship at the Montreal Neurological Institute and Hospital, McGill University (2013-2015), where she later served as an Attending Epileptologist and Group Leader of Epilepsy. Her research interests focus on developing novel seizure-independent EEG markers for the epileptogenic zone, investigating sleep-epilepsy interactions, and using intracranial EEG to study brain physiology during wakefulness and sleep. Her work aims to improve epilepsy diagnosis, prognosis, and treatment outcomes by better localizing the epileptic focus. Dr. Frauscher's recent publications demonstrate her continued leadership in epilepsy research, with over 170 peer-reviewed papers and an H-index of 62. Dr. Frauscher has received several prestigious awards including the Clinician-Scientist awards of the FRSQ (2018-2023), the Michael Prize of the International League against Epilepsy (2019), and the Ernst Niedermeyer Prize from the Austrian Epilepsy Society (2015). Her scholarly work has significantly advanced clinical knowledge in epilepsy and sleep medicine, establishing her as a leading figure in the field. As Director of the Duke Comprehensive Epilepsy Center and head of the ANPHY lab, Dr. Frauscher oversees a research program dedicated to advancing neuroscience through innovative approaches to studying brain activity. Her lab employs quantifiable tools to investigate neurophysiological and pathological processes related to epilepsy and sleep, with the ultimate goal of improving patient outcomes through better understanding of brain function.

• Epilepsy
• Sleep Medicine
• Electroencephalography
• +۴ مورد دیگر

Calliope Dendrou is an Associate Professor in Clinical Pathology and Inflammation at the Kennedy Institute of Rheumatology (KIR), University of Oxford, leading the Immune Disease Multiomics Laboratory. She previously held a Wellcome & Royal Society Sir Henry Dale Fellowship at the University of Oxford’s Centre for Human Genetics before joining KIR in 2023. Her research focuses on immune disease mechanisms using multiomics approaches, including genomic profiling to identify therapeutic targets across tissues and immune-mediated diseases. She co-leads large-scale projects like the Oxford-J&J Cartography Consortium and the Chan Zuckerberg Initiative’s LEGACY Network, and teaches on the MSc in Genomic Medicine program. Educational Background: BSc (Biology, Imperial College London, 2005; Forbes Memorial Medal Winner); PhD in Infection & Immunity (University of Cambridge, 2010). Postdoctoral training at the Weatherall Institute of Molecular Medicine under Prof. Lars Fugger. Research interests include immunogenetics, cytokine signaling pathways, drug repositioning, and cross-disease pathophysiology. Her work integrates single-cell and spatial transcriptomics to dissect immune-cell interactions in diseases like rheumatoid arthritis, inflammatory bowel disease, and celiac disease. Recent articles highlight her contributions to understanding vaccine adjuvant responses, Th17 cell roles in spondyloarthritis, and immune-epithelial networks in celiac disease. Collaborations emphasize multi-omic data analysis (e.g., Panpipes pipeline) and translational studies toward precision medicine. Awards: Forbes Memorial Medal (BSc), Wellcome & Royal Society Sir Henry Dale Fellowship. Leadership roles include Equality, Diversity, and Inclusion Champion and 'Single-Cell & Spatial Omics for Precision Medicine' Module Lead. Lab & Teams: Immune Disease Multiomics Lab at KIR. Active in collaborative initiatives such as the LEGACY Network, focusing on large-scale immune profiling in ancestrally diverse populations.

• Immunology
• Genomics
• Multiomics Analysis
• +۳ مورد دیگر

Marc V Fuccillo is an Associate Professor of Neuroscience at the Perelman School of Medicine, University of Pennsylvania, where he leads a research laboratory focused on understanding the neural circuit mechanisms underlying behavioral control. His work bridges molecular, synaptic, and behavioral approaches to investigate how striatal circuits regulate mouse behavior from simple motor patterns to complex goal-directed actions. Fuccillo holds dual appointments in the Neuroscience and Cell and Molecular Biology Graduate Groups at Penn and maintains an active laboratory investigating the synaptic and circuit basis of neuropsychiatric disorders. Education: B.A. in Molecular and Cellular Biology and Music Performance (Violin) from Brown University (1998) Ph.D. in Developmental Genetics from New York University School of Medicine (2007) M.D. from New York University School of Medicine (2008) Fuccillo's research centers on the synaptic and circuit mechanisms of behavioral control, with particular emphasis on striatal circuits. His laboratory employs a range of technologies including mouse genetics, in vitro electrophysiology, in vivo imaging, and quantitative behavioral analysis to explore how neural circuits of the striatum regulate behavior and how disruptions in these circuits contribute to neuropsychiatric disorders. His work has particularly focused on autism-associated abnormalities in behavioral control, examining how synaptic adhesion molecules like neuroligins and neurexins shape circuit function and behavior, with significant findings regarding D1 dopamine receptor positive medium spiny neurons in the nucleus accumbens. Analysis of Fuccillo's recent publications reveals a strong focus on striatal circuit function across multiple dimensions. His work spans molecular neuroscience (examining synaptic adhesion molecules), cellular physiology (studying specific neuron types in striatal circuits), systems neuroscience (mapping circuit connectivity), and behavioral neuroscience (quantifying motor learning and decision-making). A unifying theme is how disruptions in specific molecular pathways lead to circuit-level abnormalities that manifest as behavioral phenotypes relevant to neuropsychiatric disorders, with particular attention to autism, OCD, and schizophrenia models. Scientific Recognition: Publications in high-impact journals including Nature Neuroscience, Current Biology, Cell Reports, and Neuron Research supported by multiple NIH grants including NIMH F32, NIMH K01, and HHMI Gilliam Fellowship awards for lab members Fuccillo actively mentors a diverse group of trainees including postdoctoral fellows, graduate students, and undergraduates. His laboratory has produced numerous successful alumni who have gone on to faculty positions, medical residencies, and graduate programs at prestigious institutions. His mentoring approach emphasizes technical skill development across multiple neuroscience disciplines while fostering independent scientific thinking. Current research in his lab is supported by NIH funding focused on understanding the molecular architecture of striatal circuits and their role in behavioral control, with three major research directions exploring molecular logic of striatal circuits, circuit mechanisms of behavioral control, and striatal dysfunction in neuropsychiatric disease models. The Fuccillo Laboratory operates within the Department of Neuroscience at the University of Pennsylvania, with access to state-of-the-art facilities for molecular, electrophysiological, imaging, and behavioral neuroscience research. The lab maintains active collaborations with other neuroscience research groups at Penn and beyond, creating a rich intellectual environment for studying the neural basis of behavior. Current research directions include investigating whether there is a molecular logic to striatal circuit composition, how striatal circuits shape behavioral control, and what mouse models of autism, schizophrenia, and OCD can reveal about striatal circuit dysfunction in disease pathophysiology.

• Synaptic transmission
• striatal circuits
• inhibition
• +۹ مورد دیگر

Dr. Ahmed Mahrous Abouzaid is an Adjunct Professor affiliated with the School of Cardiovascular & Metabolic Health at the University of Glasgow . His research focuses on cardiovascular disease, particularly angina management, myocardial infarction pathophysiology, and clinical trial methodologies. He specializes in advanced diagnostic techniques like electrocardiography stress testing, cardiovascular magnetic resonance (CMR), and fractional flow reserve (FFR) analysis. His work emphasizes translating clinical research into improved patient outcomes, with a focus on non-obstructive coronary artery disease, left ventricular remodeling, and optimizing treatment strategies for non-ST elevation myocardial infarction (NSTEMI). He has contributed to high-impact studies published in journals such as European Heart Journal and Circulation . Recent research highlights include a 2024 randomized controlled trial evaluating invasive endotyping in angina patients and a 2025 study on electrocardiography stress testing for diagnostic accuracy. While no awards are explicitly listed, his publications reflect a strong commitment to advancing cardiovascular diagnostics and clinical practice. No grants or advising details are provided in the available text. His affiliation suggests active participation in collaborative research within the School's cardiovascular health initiatives.

• Cardiology
• Cardiovascular Medicine
• Heart Disease
• +۳ مورد دیگر

Tim Q. Duong, Ph.D., is a Professor at Albert Einstein College of Medicine, affiliated with the Departments of Radiology, Biochemistry, Ophthalmology & Visual Sciences, and Neuroscience. His research focuses on medical imaging, MRI, image analysis, machine learning, and predictive modeling for studying diseases like COVID-19 , neurodegeneration (Alzheimer's, multiple sclerosis), brain injuries , and breast cancer . Develops AI-driven MRI techniques for early disease detection Investigates neuroplasticity in glaucoma and diabetic retinopathy Leads grants from NIH and National Eye Institute Research Trends : Recent publications emphasize AI integration in medical imaging, long-term effects of SARS-CoV-2, and advanced MRI applications for ocular and neurological disorders. Grants include multiple R01 awards for diabetic retinopathy and glaucoma studies. Training Opportunities : Actively recruits postdocs, research coordinators, and faculty. Offers research positions for graduate, medical, and high school students, including Regeneron Scholar programs. Labs & Teams : Leads the Duong Lab at Montefiore Medical Center, focusing on translational research for clinical imaging solutions.

• Medical Imaging
• MRI
• Image Analysis
• +۹ مورد دیگر

Alessandra Meddis serves as an Assistant Professor in the Section of Biostatistics within the Department of Public Health at the University of Copenhagen's Faculty of Health and Medical Sciences. Her academic work centers on developing and applying advanced statistical methodologies for longitudinal and time-to-event data analysis, with significant contributions to public health research in Denmark and internationally. Her institutional affiliation is clearly established through university contact details and departmental listings. Her primary research interests include correlated survival data analysis, competing risk modeling, informative cluster size methodology, causal inference techniques for observational studies, and environmental epidemiology applications. Dr. Meddis has developed specialized expertise in handling complex survival data structures while maintaining focus on real-world public health problems, particularly in HIV comorbidity patterns, environmental exposure effects, and pandemic-related mortality analyses. Her methodological innovations directly address challenges in clustered and censored data common across medical research domains. Analysis of Dr. Meddis's recent publication record reveals a consistent trajectory of high-impact interdisciplinary research spanning clinical medicine, epidemiology, and statistical methodology. Her work appears in leading journals across biostatistics, infectious diseases, and public health, demonstrating strong collaborative networks with clinical researchers and epidemiologists. Key thematic areas include HIV treatment outcomes, environmental health exposures, and critical care applications during the pandemic, with recent methodological papers advancing survival analysis techniques for complex data structures. Scientific Awards: No scientific awards were specified in the available institutional profile. Advising and Grants: The institutional profile does not provide details regarding graduate student supervision or specific research grant funding. Her collaborative publications suggest involvement in multi-investigator projects including the COCOMO HIV cohort study and pandemic-related research initiatives. Labs and Teams: Dr. Meddis is affiliated with the Section of Biostatistics within the Department of Public Health, though specific laboratory facilities or dedicated research teams are not described in the source material. Her extensive co-authorship patterns indicate active participation in multiple research consortia across medical specialties.

• Longitudinal Data Analysis
• Time-to-Event Analysis
• Survival Analysis
• +۵ مورد دیگر

Dr. Susan Hua is an Associate Professor at the University of Newcastle's School of Biomedical Sciences and Pharmacy, specializing in translational nanopharmaceutics and therapeutic targeting. She established the first translational nanopharmaceutics laboratory in the Hunter region, focusing on drug delivery systems for gastrointestinal, musculoskeletal, and reproductive pathologies. Education: Bachelor of Pharmacy with Honours, University of Queensland (UQ) PhD in Neuroscience and Nanotechnology, UQ Research Interests: Her work centers on using nanotechnology to create targeted drug delivery systems for diseases such as chronic pain, inflammatory conditions, and obstetric complications. Key focuses include oxytocin receptor-targeted liposomes for uterine therapies and localized drug delivery to bypass biological barriers. Awards & Recognition: 2020 DVC(A) Educator Innovation Award 2017 NSW Premier's Early Career Researcher of the Year 2015 HMRI Early Career Researcher of the Year Grants & Collaborations: A/Prof Hua has secured over $5.5M in grants, including NHMRC and ARC funding. She collaborates with institutions like HMRI, John Hunter Hospital, and global teams on projects like nanoparticle-based treatments for preterm labor and uterine hemorrhage. Teaching & Leadership: She coordinates pharmacy programs, emphasizing clinical application and innovation. Her courses include Pharmacotherapeutics and Pharmacy Practice, with awards for teaching excellence (2020, 2011). Labs & Programs: Head of Therapeutic Targeting Program, University of Newcastle Director, Translational Pharmaceutics & Medical Technologies Theme (HMRI)

• Nanomedicine
• Therapeutic Targeting
• Drug Delivery Systems
• +۴ مورد دیگر

Professor Victor Fung is a leading academic in neurology and motor control at the Sydney Medical School , University of Sydney. He serves as Director of the Movement Disorders Unit at Westmead Hospital and holds prominent roles in the International Parkinson and Movement Disorder Society (President) and the Asia Pacific Affairs Committee of the Australian and New Zealand Association of Neurologists. His research focuses on Parkinson's disease , dystonia , tremor , and movement disorder genetics , with over 250 peer-reviewed publications and an h-index of 61. His work spans Clinical trials for Parkinson's treatments (e.g., foslevodopa/foscarbidopa infusion, incobotulinumtoxinA) Genetic studies on dystonia and Parkinsonism Neurophysiological assessments of tremor and balance Development of screening tools for dystonia and Parkinson's complications Key article trends highlight genetic diversity in dystonia, neuroinflammatory mechanisms in tremor, and behavioral neurology in Parkinson's disease. He contributes to editorial boards of npj Parkinson's Disease , Journal of Clinical Movement Disorders , and Faculty Opinions . While no explicit student lists are provided, his collaborations span global institutions. His clinical work at Westmead Hospital addresses device-assisted therapies and complex movement disorders.

• Neurology
• Movement Disorders
• Parkinson's Disease
• +۶ مورد دیگر